Exhibitor

Optellum is developing the world’s first software for personalized early diagnosis & treatment of lung cancer, based on Artificial Intelligence & Machine Learning. It provides a 1) patient management platform for incidental and screen-detected pulmonary nodules 2) Lung Cancer Prediction digital biomarker (malignancy rule-out & rule-in test). We are showcasing the world's first prospective multi-center trial of a lung cancer prediction digital biomarker, led by Oxford University Hospitals with co-authors of BTS & NICE guidelines.